Recilisib sodium | ON01210 (Na) | CAS#334969-03-8 | radioprotectant

MedKoo Cat#: 206119 | Name: Recilisib sodium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Recilisib sodium, also known as ON 01210.Na, is a radioprotectant which modifies cell cycle distribution patterns in cancer cells subjected to radiation therapy, and it has been identified as a potential candidate for radiation protection studies. Recilisib sodium had no effect on cells in 0 Gy in a study assessing drug dosage response towards radiation therapy on cancer cells.

Chemical Structure

Recilisib sodium

CAS#922139-31-9 (sodium)

Theoretical Analysis

MedKoo Cat#: 206119

Name: Recilisib sodium

CAS#: 922139-31-9 (sodium)

Chemical Formula: C16H12ClNaO4S

Exact Mass: 0.0000

Molecular Weight: 358.77

Elemental Analysis: C, 53.57; H, 3.37; Cl, 9.88; Na, 6.41; O, 17.84; S, 8.94

Price and Availability

Size	Price	Availability
10mg	USD 150.00	Ready to ship
25mg	USD 250.00	Ready to ship
50mg	USD 450.00	Ready to ship
100mg	USD 750.00	Ready to ship
200mg	USD 1,250.00	Ready to ship
500mg	USD 1,950.00	Ready to ship
1g	USD 2,750.00	Ready to ship
2g	USD 4,250.00	Ready to ship
5g	USD 7,950.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

334969-03-8 (free base) 922139-31-9 (sodium)

Synonym

Recilisib sodium; ON 01210.Na; ON-01210; ON01210; ON01210; Brand name: Ex-RAD

IUPAC/Chemical Name

sodium (E)-4-(2-((4-chlorobenzyl)sulfonyl)vinyl)benzoate

InChi Key

PRFBWBYKWZVQJF-RRABGKBLSA-M

InChi Code

InChI=1S/C16H13ClO4S.Na/c17-15-7-3-13(4-8-15)11-22(20,21)10-9-12-1-5-14(6-2-12)16(18)19;/h1-10H,11H2,(H,18,19);/q;+1/p-1/b10-9+;

SMILES Code

O=C([O-])C1=CC=C(/C=C/S(=O)(CC2=CC=C(Cl)C=C2)=O)C=C1.[Na+]

Appearance

white solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Related CAS# CAS#334969-03-8 (Recilisib free) CAS#922139-31-9 (Recilisib sodium)

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#A8T05K10

QC Data

View QC data: current batch, Lot#A8T05K10

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

TBD

In vitro activity:

In this report ON01210.Na provides significant dose dependent radiation protection both In Vitro and In Vivo (Figure 1, Figure 5) by protecting the hematopoietic system. ON01210.Na, unlike many of the other compounds in this library, was non-toxic to normal cells derived from human fetal lung fibroblasts (HFL cells), HUVECs (Figure 2) and to normal human bone marrow cells (Figure 4). ON01210.Na has the chemical characteristics necessary for large-scale production and long-term stability necessary for administration to a large number of first responders (data not shown). This compound was also found to be water soluble and orally bio-available with very favorable pharmacokinetic properties in multiple routes of administration (data not shown). Reference: PLoS One. 2013; 8(3): e58355. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3591351/

In vivo activity:

Mice that received Ex-RAD (Recilisib) doses of 500 mg/kg exhibited a significant increase in survival as compared with either vehicle control group or the lowest dose of Ex-RAD, 25 mg/kg treated group (P < 0.0033, Fisher's exact test). No apparent toxicity was observed with the highest dose (500 mg/kg) used in this study. Surviving animals were healthy at the end of the study (30 day after radiation). The optimal 500 mg/kg dose was used to obtain the DRF for Ex-RAD. The drug was administered to mice 24 h and 15 min (two doses) before TBI at various radiation doses, and survival data were used to evaluate the DRF. Reference: J Radiat Res. 2012 Jul; 53(4): 526–536. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3393340/

Preparing Stock Solutions

The following data is based on the product molecular weight 358.77 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Kang AD, Cosenza SC, Bonagura M, Manair M, Reddy MV, Reddy EP. ON01210.Na (Ex-RAD®) mitigates radiation damage through activation of the AKT pathway. PLoS One. 2013;8(3):e58355. doi: 10.1371/journal.pone.0058355. Epub 2013 Mar 7. PMID: 23505494; PMCID: PMC3591351. 2. Li Y, Girgis M, Wise SY, Fatanmi OO, Seed TM, Maniar M, Cheema AK, Singh VK. Analysis of the metabolomic profile in serum of irradiated nonhuman primates treated with Ex-Rad, a radiation countermeasure. Sci Rep. 2021 Jun 1;11(1):11449. doi: 10.1038/s41598-021-91067-9. PMID: 34075191; PMCID: PMC8169671. 4. Ghosh SP, Kulkarni S, Perkins MW, Hieber K, Pessu RL, Gambles K, Maniar M, Kao TC, Seed TM, Kumar KS. Amelioration of radiation-induced hematopoietic and gastrointestinal damage by Ex-RAD(R) in mice. J Radiat Res. 2012 Jul;53(4):526-36. doi: 10.1093/jrr/rrs001. Epub 2012 Jun 6. PMID: 22843617; PMCID: PMC3393340.

In vitro protocol:

In vivo protocol:

1. Li Y, Girgis M, Wise SY, Fatanmi OO, Seed TM, Maniar M, Cheema AK, Singh VK. Analysis of the metabolomic profile in serum of irradiated nonhuman primates treated with Ex-Rad, a radiation countermeasure. Sci Rep. 2021 Jun 1;11(1):11449. doi: 10.1038/s41598-021-91067-9. PMID: 34075191; PMCID: PMC8169671. 2. Ghosh SP, Kulkarni S, Perkins MW, Hieber K, Pessu RL, Gambles K, Maniar M, Kao TC, Seed TM, Kumar KS. Amelioration of radiation-induced hematopoietic and gastrointestinal damage by Ex-RAD(R) in mice. J Radiat Res. 2012 Jul;53(4):526-36. doi: 10.1093/jrr/rrs001. Epub 2012 Jun 6. PMID: 22843617; PMCID: PMC3393340.

1: Kang AD, Cosenza SC, Bonagura M, Manair M, Reddy MV, Reddy EP. ON01210.Na (Ex-RADÂ®) mitigates radiation damage through activation of the AKT pathway. PLoS One. 2013;8(3):e58355. doi: 10.1371/journal.pone.0058355. Epub 2013 Mar 7. PubMed PMID: 23505494; PubMed Central PMCID: PMC3591351. 2: Tamhane M, Maniar M, Ren C, Benzeroual KE, Taft DR. Disposition of ON 01210.Na (Ex-RAD(R)), a novel radioprotectant, in the isolated perfused rat liver: probing metabolic inhibition to increase systemic exposure. J Pharm Sci. 2013 Feb;102(2):732-40. doi: 10.1002/jps.23391. Epub 2012 Dec 4. PubMed PMID: 23212688. 3: Ghosh SP, Kulkarni S, Perkins MW, Hieber K, Pessu RL, Gambles K, Maniar M, Kao TC, Seed TM, Kumar KS. Amelioration of radiation-induced hematopoietic and gastrointestinal damage by Ex-RAD(R) in mice. J Radiat Res. 2012 Jul;53(4):526-36. doi: 10.1093/jrr/rrs001. Epub 2012 Jun 6. PubMed PMID: 22843617; PubMed Central PMCID: PMC3393340. 4: Suman S, Datta K, Doiron K, Ren C, Kumar R, Taft DR, Fornace AJ Jr, Maniar M. Radioprotective effects of ON 01210.Na upon oral administration. J Radiat Res. 2012;53(3):368-76. Epub 2012 May 11. PubMed PMID: 22739006. 5: Suman S, Maniar M, Fornace AJ Jr, Datta K. Administration of ON 01210.Na after exposure to ionizing radiation protects bone marrow cells by attenuating DNA damage response. Radiat Oncol. 2012 Jan 20;7:6. doi: 10.1186/1748-717X-7-6. PubMed PMID: 22264334; PubMed Central PMCID: PMC3275448. 6: Bhattacharjee Y. Devastation in Japan. Candidate radiation drugs inch forward. Science. 2011 Mar 25;331(6024):1505. doi: 10.1126/science.331.6024.1505. PubMed PMID: 21436412. 7: Chun AW, Freshwater RE, Taft DR, Gillum AM, Maniar M. Effects of formulation and route of administration on the systemic availability of Ex-RADÂ®, a new radioprotectant, in preclinical species. Biopharm Drug Dispos. 2011 Mar;32(2):99-111. doi: 10.1002/bdd.741. Epub 2011 Jan 14. PubMed PMID: 21341279. 8: Ghosh SP, Perkins MW, Hieber K, Kulkarni S, Kao TC, Reddy EP, Reddy MV, Maniar M, Seed T, Kumar KS. Radiation protection by a new chemical entity, Ex-Rad: efficacy and mechanisms. Radiat Res. 2009 Feb;171(2):173-9. doi: 10.1667/RR1367.1. PubMed PMID: 19267542. 9: Fernandes PP, Maniar M, Dash AK. Development and validation of a sensitive liquid chromatographic method for the analysis of a novel radioprotectant: ON 01210.Na. J Pharm Biomed Anal. 2007 Apr 11;43(5):1796-803. Epub 2006 Dec 20. PubMed PMID: 17184951. 10: Wen, K. K., Roy, S., Grumbach, I. M., & Wu, M. (2021). A “failed” assay development for the discovery of rescuing small molecules from the radiation damage. SLAS DISCOVERY: Advancing the Science of Drug Discovery, 26(10), 1315-1325.